Results 311 to 320 of about 2,436,024 (405)

[Retracted] Prognostic significance of miR‑218 in human hepatocellular carcinoma and its role in cell growth. [PDF]

Oncol Rep
Tu K, Li C, Zheng X, Yang W, Yao Y, Liu Q.   +5 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Precision Oncology 2.0: Guiding Magic Bullets With Expression-Based Liquid Biopsy. [PDF]

J Clin Oncol
Gulati GS, Choueiri TK, Freedman ML, Baca SC.   +3 more
europepmc   +1 more source

The Management of Nasal Cavity and Paranasal Sinuses Cancers: Experience of Radiation Oncology Department of Mohamed VI Teaching Hospital of Marrakech

Youness El-Khadir, Ghita Hadraoui, Rokkaya Iharti, Mouna Darfaoui, Samir Barkiche, N. Oumghar, Abdelhamid El Omrani, Mouna Khouchani   +7 more
openalex   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Attitudes toward large language model-based Artificial Intelligence systems as an information source for shared decision-making in radiation oncology. [PDF]

Oncologist
Moser R, Buchecker LM, Nano J, Mayr NA, Behzadi ST, Kiesl S, Maier S, Allwohn L, Lammert J, Adams LC, Tschochohei M, Combs SE, Borm KJ.   +12 more
europepmc   +1 more source

Embracing the digital frontier: A perspective on social media's impact in transforming global oncology communication

Viviana Cortiana, Harshal Chorya, Harshitha Vallabhaneni, Diksha Mahendru, Jade Gambill, William B. Wilkerson, Chandler H. Park, Yan Leyfman   +7 more
openalex   +2 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Correction: Influence factor and mechanism of FLASH effect. [PDF]

Front Oncol
Feng T, He T, Ye W, Xiang L.
europepmc   +1 more source

Theragnostic approach of venous malformations in 2025: Similarities and differences with oncology advances

A. Dompmartin, Juliette Méry De Montigny, Jean Matthieu L’ORPHELIN   +2 more
openalex   +1 more source